diosbulbin-b has been researched along with ferulic-acid* in 4 studies
4 other study(ies) available for diosbulbin-b and ferulic-acid
Article | Year |
---|---|
Ferulic acid prevents Diosbulbin B-induced liver injury by inhibiting covalent modifications on proteins.
Diosbulbin B (DIOB) has been reported to cause serious liver injury. However, in traditional medicine, DIOB-containing herbs are highly safe in combination with ferulic acid (FA)-containing herbs, suggesting potential neutralizing effect of FA on the toxicity of DIOB. DIOB can be metabolized to generate reactive metabolites (RMs), which can covalently bind to proteins and lead to hepatoxicity. In the present study, the quantitative method was firstly established for investigating the correlation between DIOB RM-protein adducts (DRPAs) and hepatotoxicity. Then, we estimated the detoxication effect of FA in combination with DIOB and revealed the underlying mechanism. Our data indicated that the content of DRPAs positively correlate with the severity of hepatotoxicity. Meanwhile, FA is able to reduce the metabolic rate of DIOB in vitro. Moreover, FA suppressed the production of DRPAs and decreased the serum alanine/aspartate aminotransferase (ALT/AST) levels elevated by DIOB in vivo. Thus, FA can ameliorate DIOB-induced liver injury through reducing the production of DRPAs. Topics: Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Proteins | 2023 |
Ferulic acid prevents liver injury induced by Diosbulbin B and its mechanism.
The rhizome of Dioscorea bulbifera Linn, traditionally used to treat thyroid disease and cancer in China, is reported to induce serious liver injury during clinical practice. Diosbulbin B (DB), a diterpene lactone, has been found to be the main toxic compound in D. bulbifera. The present study aims to investigate the protection of ferulic acid (FA) against DB-induced acute liver injury and its engaged mechanism. Mice were orally administered FA (20, 40, 80 mg/kg) once daily for 6 consecutive days; and then orally given DB (250 mg/kg) on the last day. Daily FA (40, 80 mg/kg) decreased DB (250 mg/kg)-induced increase in serum levels of alanine/aspartate aminotransferase (ALT/AST) and alkaline phosphatase (ALP). Histological evaluation showed that FA (80 mg/kg) ameliorated DB-induced hepatocellular degeneration and lymphocyte infiltration. Results of terminal dUTP nick-end labeling (TUNEL) staining assay showed that FA (80 mg/kg) decreased the DB-increased number of apoptotic hepatocytes. FA (40, 80 mg/kg) reduced DB-increased liver malondialdehyde (MDA) amount. FA (40, 80 mg/kg) decreased DB-increased serum levels of tumor necrosis factor alpha (TNF-α) and interferon-γ (IFN-γ), and liver myeloperoxidase (MPO) activity. FA (80 mg/kg) reversed the DB-induced decrease in expression of inhibitor of kappa B (IκB) and the increase in nuclear translocation of the p65 subunit of nuclear factor kappa B (NFκBp65). Taken together, our results demonstrate that FA prevents DB-induced acute liver injury via inhibiting intrahepatic inflammation and liver apoptosis. Topics: Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Coumaric Acids; Heterocyclic Compounds, 4 or More Rings; Interferon-gamma; Liver; Male; Mice; Mice, Inbred ICR; NF-kappa B | 2016 |
Ferulic acid prevents liver injury and increases the anti-tumor effect of diosbulbin B in vivo.
The present study is designed to investigate the protection by ferulic acid against the hepatotoxicity induced by diosbulbin B and its possible mechanism, and further observe whether ferulic acid augments diosbulbin B-induced anti-tumor activity. The results show that ferulic acid decreases diosbulbin B-increased serum alanine transaminase/aspartate transaminase (ALT/AST) levels. Ferulic acid also decreases lipid peroxide (LPO) levels which are elevated in diosbulbin B-treated mice. Histological evaluation of the liver demonstrates hydropic degeneration in diosbulbin B-treated mice, while ferulic acid reverses this injury. Moreover, the activities of copper- and zinc-containing superoxide dismutase (CuZn-SOD) and catalase (CAT) are decreased in the livers of diosbulbin B-treated mice, while ferulic acid reverses these decreases. Further results demonstrate that the mRNA expressions of CuZn-SOD and CAT in diosbulbin B-treated mouse liver are significantly decreased, while ferulic acid prevents this decrease. In addition, ferulic acid also augments diosbulbin B-induced tumor growth inhibition compared with diosbulbin B alone. Taken together, the present study shows that ferulic acid prevents diosbulbin B-induced liver injury via ameliorating diosbulbin B-induced liver oxidative stress injury and augments diosbulbin B-induced anti-tumor activity. Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Coumaric Acids; Dose-Response Relationship, Drug; Drug Synergism; Heterocyclic Compounds, 4 or More Rings; Male; Mice; Mice, Inbred ICR; Oxidative Stress; Reactive Oxygen Species; Sarcoma; Treatment Outcome | 2014 |
Protection of Angelica sinensis (Oliv) Diels against hepatotoxicity induced by Dioscorea bulbifera L. and its mechanism.
Dioscorea bulbifera L., a traditionally used medicinal plant in China, is reported to induce hepatotoxicity. The present study is designed to investigate the protection of an ethanol extract of Angelica sinensis (Oliv) Diels (AE) against an ethyl acetate fraction of D. bulbifera (EF)-induced liver injury and its engaged mechanism. High performance liquid chromatography (HPLC) analysis showed that the amount of diosbulbin B in EF was 16.03% and ferulic acid in AE was 0.18%. EF (350 mg/kg) increased serum alanine/aspartate aminotransferase (ALT/AST), alkaline phosphatase (ALP) activities and total bilirubin (TB) amount, while AE inhibited such an increase. Liver histological evaluation showed that AE prevented development of severe hepatic lesions induced by EF. Further results showed that EF decreased the expression of Bcl-2 and induced the cleaved activation of caspase-9 and -3, and all those effects were reversed by AE. AE also reversed EF-induced decreased expression of the inhibitor of kappa B (IκB), superoxide dismutase (SOD), and glutathione peroxidase (GPx). Taken together, our results demonstrate that AE can prevent EF-induced hepatotoxicity via preventing apoptosis, meanwhile IκB, SOD, and GPx may be involved in such protection. Topics: Angelica sinensis; Animals; Apoptosis; Biomarkers; Chemical and Drug Induced Liver Injury; Coumaric Acids; Dioscorea; Heterocyclic Compounds, 4 or More Rings; Liver; Male; Medicine, Traditional; Mice, Inbred ICR; Oxidative Stress; Plant Extracts; Protective Agents; Superoxide Dismutase | 2014 |